NLS Pharmaceutics Reports Positive Results in Fentanyl Study

The latest update is out from NLS Pharmaceutics ( (NLSP) ).

On April 15, 2025, NLS Pharmaceutics announced positive results from a preclinical study demonstrating that Mazindol can reduce fentanyl-induced reward in animal models, highlighting its potential as a non-opioid treatment for fentanyl use disorder. This development positions Mazindol as a differentiated asset in addiction therapeutics, with potential expansion into high-value markets beyond ADHD and narcolepsy. The announcement follows NLS’s recent financial moves, including a $3 million raise and a $25 million equity facility agreement as part of a strategic merger with Kadimastem Ltd., aimed at enhancing the development of both companies’ clinical assets.

More about NLS Pharmaceutics

NLS Pharmaceutics Ltd. is a Swiss clinical-stage biopharmaceutical company dedicated to developing innovative treatments for central nervous system disorders, including ADHD, narcolepsy, and substance use disorders. The company’s lead compound, Mazindol ER, is being investigated across several indications due to its unique pharmacological action on monoaminergic, opioid, serotonergic, and orexinergic systems.

YTD Price Performance: -33.49%

Average Trading Volume: 2,048,152

Technical Sentiment Signal: Buy

Current Market Cap: $3.59M

See more insights into NLSP stock on TipRanks’ Stock Analysis page.